DYADIC INTERNATIONAL INC Foreign Currency Transaction Loss, before Tax
DYADIC INTERNATIONAL INC (DYAI) reported Foreign Currency Transaction Loss, before Tax of $46.90 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-25.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:ForeignCurrencyTransactionLossBeforeTax · last filed 2026-03-25
- DYADIC INTERNATIONAL INC foreign currency transaction loss, before tax for the quarter ending 2025-12-31 was $10.97K, a 28.86% increase year-over-year.
- DYADIC INTERNATIONAL INC foreign currency transaction loss, before tax for the quarter ending 2025-09-30 was $12.76K, a 112.76% increase year-over-year.
- DYADIC INTERNATIONAL INC foreign currency transaction loss, before tax for the quarter ending 2025-06-30 was $16.10K, a 411.70% increase year-over-year.
- DYADIC INTERNATIONAL INC foreign currency transaction loss, before tax for the quarter ending 2025-03-31 was $7.07K.
- DYADIC INTERNATIONAL INC foreign currency transaction loss, before tax for fiscal 2025 was $46.90K, a 107.88% increase from fiscal 2024.
- DYADIC INTERNATIONAL INC foreign currency transaction loss, before tax for fiscal 2024 was $22.56K.
| Period end | Foreign Currency Transaction Loss, before Tax 3 month | Foreign Currency Transaction Loss, before Tax 6 month | Foreign Currency Transaction Loss, before Tax 9 month | Foreign Currency Transaction Loss, before Tax 12 month |
|---|---|---|---|---|
| 2025-12-31 | $10.97K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $23.73K derived: sum of 2 quarters · filed 2026-03-25 | $39.83K derived: sum of 3 quarters · filed 2026-03-25 | $46.90K 10-K · filed 2026-03-25 |
| 2025-09-30 | $12.76K 10-Q · filed 2025-11-12 | $28.85K derived: sum of 2 quarters · filed 2025-11-12 | $35.92K 10-Q · filed 2025-11-12 | $44.44K derived: sum of 4 quarters · filed 2026-03-25 |
| 2025-06-30 | $16.10K 10-Q · filed 2025-08-13 | $23.17K 10-Q · filed 2025-08-13 | $31.69K derived: sum of 3 quarters · filed 2026-03-25 | $37.68K derived: sum of 4 quarters · filed 2026-03-25 |
| 2025-03-31 | $7.07K derived: 10-K 12 month − 3 quarters · filed 2026-03-25 | $15.59K derived: sum of 2 quarters · filed 2026-03-25 | $21.58K derived: sum of 3 quarters · filed 2026-03-25 | $24.73K derived: sum of 4 quarters · filed 2026-03-25 |
| 2024-12-31 | $8.52K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $14.51K derived: sum of 2 quarters · filed 2026-03-25 | $17.66K derived: sum of 3 quarters · filed 2026-03-25 | $22.56K 10-K · filed 2026-03-25 |
| 2024-09-30 | $6.00K 10-Q · filed 2025-11-12 | $9.14K derived: sum of 2 quarters · filed 2025-11-12 | $14.04K 10-Q · filed 2025-11-12 | |
| 2024-06-30 | $3.15K 10-Q · filed 2025-08-13 | $8.05K 10-Q · filed 2025-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |